Which Biomarkers Are Effective for Identifying Th2-Driven Inflammation in Asthma?
(2013) In Current Allergy and Asthma Reports 13(5). p.477-486- Abstract
- Recognition of asthma as a heterogeneous disease revealed different potential molecular targets and urged the development of targeted, customized treatment modalities. Evidence was provided for different inflammatory subsets of asthma and more recently, further refined to T helper (Th)2-high and Th2-low subphenotypes with different responsiveness to standard and targeted pharmacotherapy. Given these differences in immunology and pathophysiology, proof of concept studies of novel treatment modalities for asthma should be performed in adequate, well-defined phenotypes. In this review, we describe both existing and novel biomarkers of Th2-inflammation in asthma that can be applied to classify asthma subphenotypes in clinical studies and for... (More)
- Recognition of asthma as a heterogeneous disease revealed different potential molecular targets and urged the development of targeted, customized treatment modalities. Evidence was provided for different inflammatory subsets of asthma and more recently, further refined to T helper (Th)2-high and Th2-low subphenotypes with different responsiveness to standard and targeted pharmacotherapy. Given these differences in immunology and pathophysiology, proof of concept studies of novel treatment modalities for asthma should be performed in adequate, well-defined phenotypes. In this review, we describe both existing and novel biomarkers of Th2-inflammation in asthma that can be applied to classify asthma subphenotypes in clinical studies and for treatment monitoring. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4006156
- author
- Diamant, Zuzana LU ; Tufvesson, Ellen LU and Bjermer, Leif LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Current Allergy and Asthma Reports
- volume
- 13
- issue
- 5
- pages
- 477 - 486
- publisher
- Springer
- external identifiers
-
- wos:000324492400009
- pmid:23918590
- scopus:84885172146
- ISSN
- 1534-6315
- DOI
- 10.1007/s11882-013-0376-6
- language
- English
- LU publication?
- yes
- id
- 0cbfd7d5-1a03-46f8-8e3a-fa153e4a93b4 (old id 4006156)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23918590?dopt=Abstract
- date added to LUP
- 2016-04-01 11:14:32
- date last changed
- 2022-03-20 03:52:05
@article{0cbfd7d5-1a03-46f8-8e3a-fa153e4a93b4,
abstract = {{Recognition of asthma as a heterogeneous disease revealed different potential molecular targets and urged the development of targeted, customized treatment modalities. Evidence was provided for different inflammatory subsets of asthma and more recently, further refined to T helper (Th)2-high and Th2-low subphenotypes with different responsiveness to standard and targeted pharmacotherapy. Given these differences in immunology and pathophysiology, proof of concept studies of novel treatment modalities for asthma should be performed in adequate, well-defined phenotypes. In this review, we describe both existing and novel biomarkers of Th2-inflammation in asthma that can be applied to classify asthma subphenotypes in clinical studies and for treatment monitoring.}},
author = {{Diamant, Zuzana and Tufvesson, Ellen and Bjermer, Leif}},
issn = {{1534-6315}},
language = {{eng}},
number = {{5}},
pages = {{477--486}},
publisher = {{Springer}},
series = {{Current Allergy and Asthma Reports}},
title = {{Which Biomarkers Are Effective for Identifying Th2-Driven Inflammation in Asthma?}},
url = {{https://lup.lub.lu.se/search/files/2498813/4054023.pdf}},
doi = {{10.1007/s11882-013-0376-6}},
volume = {{13}},
year = {{2013}},
}